


Claims:

1. A compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl.

2. A compound according to claim 1, or pharmaceutical acceptable salts or solvates thereof, wherein:

R₁ is phenyl, or substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl,

R₂ is H, CH₃, substituted alkyl or substituted phenyl, and

R₃ is substituted phenyl, C₅ to C₆ heteroaryl or C₅ to C₆ substituted heteroaryl.

3. A compound according to claim 2, or pharmaceutical acceptable salts or solvates thereof, wherein:


R₁ is substituted phenyl,

R₂ is CH₃ or substituted alkyl, and

R₃ is substituted phenyl or substituted C₅ heteroaryl.

4. A compound according to claim 1, having the following formula (2)

formula (2)



wherein:


R₂ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl,

R₄ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl, and

R₅ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl.

5. A compound according to any of claims 1 to 4 having the following formula (3)

formula (3)




wherein:

R₂ is H, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide or C₁ to C₈ aminoacyl, C₁ to C₈ alkoxy.

6. A compound according to any of claims 1 to 4 having the following formula (4)

formula (4)



wherein:

R₂ is H, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide or C₁ to C₈ aminoacyl, C₁ to C₈ alkoxy.

7. A compound according to any of claims 1 to 6 wherein said compound is capable of binding the NR3B1 receptor protein or a portion thereof according to SEQ ID NO. 3 or a mammalian homologue thereof.
8. A compound according to any of claims 1 to 6 wherein said compound is capable of modulating the activity of the NR3B1 receptor protein comprising antagonistic or agonistic effects.
9. A method for prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to any of claims 1 to 6 wherein the prevention or treatment is directly or indirectly accomplished

through the binding of the compound according to any of claims 1 to 8 to the NR3B1 receptor protein or to the NR3B1 receptor protein homologue.

10. A method for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 9 wherein the mammal is a human.
11. A method for regulating physiologies that are influenced by estrogenic response pathways in a mammal comprising modulating the activity of the NR3B1 receptor with a therapeutically effective amount of a compound according to any of claims 1 to 8.
12. A method of treating in mammal a disease which is directly or indirectly affected by estrogen levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 8.
13. A method of treating cancer, osteoporosis, obesity, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 8.
14. A method of modulating the expression of a gene directly or indirectly controlled by NR3B1 in tissues of a mammal comprising administering to a mammal in need of such modulation an effective amount of a compound according to any of claims 1 to 8.
15. The method of claim 13 or 14, wherein said mammal is a human.
16. Use of a method according to claim 15 for treating cancer, osteoporosis, lipid disorders or a cardiovascular disorder in humans or influencing fertility and reproductive health.
17. A method according to claim 14 wherein the expression of genes comprising aromatase, MCAD, thyroid receptor alpha, osteopontin, PS2, lactoferrin is modulated.
18. Use of a compound according to any of the claims 1 to 8 as a medicament.

19. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for the prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 8 to the NR3B1 receptor protein or NR3B1 receptor protein homologue.
20. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 19 wherein the mammal is a human.
21. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for regulating estrogenic signaling systems in a mammal by modulating the NR3B1 receptor.
22. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for regulating levels of aromatase, bone morphogenic, and/or lipogenic factors or proteins.
23. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for treating in a mammal cancer, osteoporosis, obesity, atherosclerosis, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health.
24. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament capable for blocking in a mammal the proliferation of estrogen receptor positive and estrogen receptor negative cells, in particular cancer cells.
25. Use of the compound according to claim 24 for the manufacture of a medicament for treating obesity in a mammal, in particular a human.
26. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR3B1 receptor.